Overall survival rates of ESCC patients with decreased nuclear expression or increased cytoplasmic expression of LOXL2 are significantly lower than those of the patients with the reverse expression pattern [17]. This evidence concerns the gene LOXL2 and esophageal squamous cell carcinoma.